We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Effect of a Single High Loading Dose of Rosuvastatin on Percutaneous Coronary Intervention for Acute Coronary Syndromes.
- Authors
Wang, Zhengzhong; Dai, Hongyan; Xing, Mingqing; Yu, Zhongxiang; Lin, Xianru; Wang, Shoudong; Zhang, Junyi; Hou, Fangjie; Ma, Ying; Ren, Yongqiang; Tan, Kai; Wang, Yanping; Ge, Zhiming
- Abstract
Objectives: A high loading dose of atorvastatin has been confirmed to reduce postprocedural events in patients undergoingpercutaneous coronary intervention (PCI). In this study, we sought to investigate the protective effects of rosuvastatin in patientswith acute coronary syndromes (ACS) undergoing PCI and to determine the effect of rosuvastatin pretreatment on the postprocedurallevels of high-sensitivity C-reactive protein (hs-CRP), interleukin 6 (IL-6), and monocyte chemotactic protein1 (MCP-1). Methods: A total of 125 patients with non-ST-segment elevation ACS were randomized to pretreatment with rosuvastatin(20 mg 2-4 hours before PCI [n = 62]) or placebo (n = 63). All the patients received subsequent long-term rosuvastatintreatment (10 mg/d). The main end point of the trial was the 30-day incidence of major adverse cardiac events (death, myocardialinfarction, or unplanned revascularization). Plasma levels of hs-CRP, IL-6, and MCP-1 were detected before PCI and 6 hours, 24hours, and 3 days after PCI. Results: The primary end point occurred in 8.1% of the patients in the rosuvastatin arm and 22.2% inthe placebo arm (P < .01); this difference was entirely attributed to a reduced incidence of myocardial infarction (8.1% vs 22.2%;P < .01). The postprocedural elevation in creatine kinase-MB and troponin I was also significantly lower in the rosuvastatin groupat 6 hours, 24 hours, and 3 days. Plasma levels of hs-CRP, IL-6, and MCP-1 increased significantly after PCI in both the rosuvastatinand control groups; however, the postprocedural elevations in hs-CRP and IL-6 levels were significantly lower in the rosuvastatingroup than the control group. Conclusions: A single, high dose (20 mg) of rosuvastatin prior to PCI reduces postproceduralmyocardial injury in patients with ACS, with a concomitant attenuation of the postprocedural increase in hs-CRP and IL-6 levels.
- Subjects
ATORVASTATIN; ROSUVASTATIN; CORONARY heart disease treatment; MYOCARDIAL infarction; INTERLEUKIN-6; THERAPEUTICS
- Publication
Journal of Cardiovascular Pharmacology & Therapeutics, 2013, Vol 18, Issue 4, p327
- ISSN
1074-2484
- Publication type
Article
- DOI
10.1177/1074248412474346